ELV
Elevance HealthPrevious close
420.07
Change
−1.95 / −0.46%
P/E (TTM) ?
17.9
Market Cap
$90.8B
1M
+8.04%
S&P 500 −0.91% over same period
Volume / Avg Volume
1.3M / 1.4M
0.90× average
Latest earnings analysisFY2026 Q3Reported 2026-10-21
Elevance Health Q3 2026: EPS beat, guidance raised, margins thin
Elevance beat on the bottom line and raised its 2026 outlook, but the quarter's profit leaned on investment income as much as on insurance operations. GAAP EPS of $6.27 topped the $4.73 consensus, and adjusted EPS rose to $6.99 from $6.03. Read the rest with that split in mind: Carelon carried the operating gain while Health Benefits margin thinned to 1.0%.
Read the full analysis →Revenue$51.43BYoY +2.70%
EPS (non-GAAP)$6.99Beatest. $4.73
Next-day move+2.57%
Recent Earnings
Click to read the FinDog analysis| Period | Reported | Revenue | Analysis |
|---|---|---|---|
| FY2026 Q3 Quarter ended 2026-09 | 2026-10-21 | $51.4B | Read analysis → |
| FY2026 Q2 Quarter ended 2026-06 | 2026-07-15 | $50.5B | Read analysis → |
| FY2026 Q1 Quarter ended 2026-03 | 2026-04-22 | $50.2B | Pending |
| FY2025 Q4 Quarter ended 2025-12 | 2026-01-28 | $199B | Pending |
| FY2025 Q3 Quarter ended 2025-09 | 2025-10-21 | $50.7B | Pending |
| FY2025 Q2 Quarter ended 2025-06 | 2025-07-17 | $49.8B | Pending |
| FY2025 Q1 Quarter ended 2025-03 | 2025-04-22 | $48.9B | Pending |
Decision Panel
Trends · Valuation · Earnings reaction · Guidance credibility — all from company filings and market dataValuation
P/E is at percentile 66 of its 5-year rangeMid-range
5-year range 11.7 – 20.4 · Median 16.2
Last 4 quarters: $2.2B in buybacks + $1.5B in dividends, 4.03% of market cap combined
P/E (TTM)
17.9
P/B
2.1
P/S
0.5
Dividend Yield
1.24%
Earnings Reaction
Over the last 7 reports, the stock moved ±3.8% on average on the first trading day after, rising 4 times
Most recent +2.57%
Volatility & Correlation
1-year beta 0.29 · Correlation with S&P 500 0.11Low beta
Annualized volatility 35% vs. 13% for the S&P 500
Insider Trading
View all →Last 90 days · Open-market buys and sells by officers and directors · Amounts in USD millions
Buy 0 · $0.00MSell 1 · $4.7MNet selling $4.7M
- 10-22Kaye MarkEVP & CFOSell$4.7M10,584 shares · 13 trades · Avg price 440.13
Multi-Quarter Financial Trends
View all quarters →Last 12 quarters · As reported by the company
| Quarter | Revenue ($B) | YoY | Gross Margin | Net Income ($B) | EPS |
|---|---|---|---|---|---|
| FY2026 Q3 | 51.43 | +1.4% | 89.0% | 1.37 | 6.27 |
| FY2026 Q2 | 50.47 | +1.4% | 89.1% | 1.46 | 6.71 |
| FY2026 Q1 | 50.18 | +2.6% | 89.1% | 1.76 | 8.00 |
| FY2025 Q4 | 49.75 | +9.5% | 88.9% | 0.55 | 2.56 |
| FY2025 Q3 | 50.71 | +12.4% | 89.4% | 1.19 | 5.32 |
| FY2025 Q2 | 49.78 | +13.4% | 89.4% | 1.74 | 7.72 |
| FY2025 Q1 | 48.89 | +14.8% | 89.8% | 2.18 | 9.61 |
| FY2024 Q4 | 45.44 | +6.6% | 86.8% | 0.42 | 1.88 |
| FY2024 Q3 | 45.11 | +5.3% | 88.7% | 1.02 | 4.36 |
| FY2024 Q2 | 43.89 | +0.5% | 89.0% | 2.30 | 9.85 |
| FY2024 Q1 | 42.58 | +1.0% | 91.0% | 2.25 | 9.59 |
| FY2023 Q4 | 42.65 | +6.8% | 88.7% | 0.86 | 3.68 |
| Ticker | P/E | Revenue YoY | Gross Margin | 1M | View |
|---|---|---|---|---|---|
| ELV | 17.9 | +1.4% | 89.0% | +8.04% | Neutral |
| LLY | 50.2 | +38.6% | 83.9% | +22.51% | Bullish |
| JNJ | 41.3 | +5.9% | 68.1% | +3.20% | Bullish |
| ABBV | 81.4 | +10.2% | 74.7% | +12.73% | Bullish |
| UNH | 23.0 | +0.4% | 88.1% | +10.87% | Bullish |
| MRK | 117.2 | +5.1% | 73.5% | +2.90% | Neutral |
| TMO | 36.4 | +9.1% | — | +3.25% | Neutral |
| AMGN | 28.5 | +9.5% | 72.0% | +10.56% | Bullish |
| GILD | — | +6.8% | 81.1% | +14.51% | Neutral |